Compare Wahed FTSE USA Shariah ETF (HLAL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Zimmer Biomet Holdings Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $75.9 (market cap $1.00B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 16.9× Wahed FTSE USA Shariah ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 66 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HLAL | ZBH | |
|---|---|---|
Market Cap | $1.00B | $16.95B |
Volume | 51,137 | 2,505,240 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $103.98 |
52-Week Low | $57.46 | $79.58 |
Typical Hold Time | 66 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.91, down 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.10 is scheduled for September 2026, indicating a long-term income component. The stock shows mixed signals with strong moving average support but overbought RSI levels.
The outlook is cautiously optimistic due to bullish moving averages, but high RSI suggests near-term pullback risk. Investment opportunity lies in technical strength, while risks include lack of recent fundamental data and potential volatility from overbought conditions. Investors should await updated financials for a clearer picture.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
